share_log

6-K: Articles of Association of Novo Nordisk A/S

6-K: Articles of Association of Novo Nordisk A/S

諾和諾德 | 6-K:諾和諾德公司章程
美股sec公告 ·  04/25 06:10
Moomoo AI 已提取核心訊息
Novo Nordisk A/S, a foreign private issuer, has submitted a Form 6-K report to the United States Securities and Exchange Commission (SEC) on April 24, 2024. The report, which is a requirement for foreign companies listed on U.S. stock exchanges, provides updates and information that the company deems significant. The submission of the Form 6-K indicates Novo Nordisk A/S's compliance with the SEC's rules, specifically Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. The document was officially signed by an authorized representative of Novo Nordisk A/S on the date of filing. The company's principal executive offices are located at Novo Allé 1, DK-2880, Bagsvaerd, Denmark.
Novo Nordisk A/S, a foreign private issuer, has submitted a Form 6-K report to the United States Securities and Exchange Commission (SEC) on April 24, 2024. The report, which is a requirement for foreign companies listed on U.S. stock exchanges, provides updates and information that the company deems significant. The submission of the Form 6-K indicates Novo Nordisk A/S's compliance with the SEC's rules, specifically Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. The document was officially signed by an authorized representative of Novo Nordisk A/S on the date of filing. The company's principal executive offices are located at Novo Allé 1, DK-2880, Bagsvaerd, Denmark.
外國私人發行人諾和諾德A/S已於2024年4月24日向美國證券交易委員會(SEC)提交了6-K表格報告。該報告是對在美國證券交易所上市的外國公司的要求,提供了該公司認爲重要的最新情況和信息。提交的6-K表格表明諾和諾德A/S遵守了美國證券交易委員會的規則,特別是1934年《證券交易法》第13a-16條或第15d-16條。該文件在提交之日由諾和諾德A/S的授權代表正式簽署。該公司的主要行政辦公室位於丹麥巴格斯瓦爾德 DK-2880 的 Novo Allé 1 號。
外國私人發行人諾和諾德A/S已於2024年4月24日向美國證券交易委員會(SEC)提交了6-K表格報告。該報告是對在美國證券交易所上市的外國公司的要求,提供了該公司認爲重要的最新情況和信息。提交的6-K表格表明諾和諾德A/S遵守了美國證券交易委員會的規則,特別是1934年《證券交易法》第13a-16條或第15d-16條。該文件在提交之日由諾和諾德A/S的授權代表正式簽署。該公司的主要行政辦公室位於丹麥巴格斯瓦爾德 DK-2880 的 Novo Allé 1 號。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息